Bridget Martell, M.D., M.A.
Dr. Martell has over 15 years of experience in the Pharmaceutical/Biotechnology industry as a Chief Medical Officer, and strategic/scientific advisor, working across all stages of clinical drug development including work on the successful approvals of Kadcyla® Elelyso ® and Intermezzo® and secondary indications for Pradaxa® and Sutent®. She has experience with large and small molecules, biosimilars, combined drug devices, and vaccines within oncology, immuno-Oncology, rheumatology, pain, orphan diseases, CNS, cardiovascular, and women’s health. She is currently Managing Director and founder of BAM Consultants, LLC, a clinical/scientific advisory firm and prior to this, was Senior Vice President of New Product Development and Chief Medical Officer of Juniper Pharmaceuticals, a public company with a focus on Women’s Health therapeutics. Dr. Martell’s previous work included leading medical affairs at Purdue Pharma and clinical development and medical affairs at Pfizer as the Biosimilars Medical Head. She also held senior clinical development roles at other business units within Pfizer’s biopharmaceutical businesses. She began her clinical investigation career at Yale with a Career Development Award and as a Faculty Auditor in the Robert Wood Johnson Clinical Scholar conducting the first therapeutic cocaine vaccine trial for adjunctive treatment for cocaine dependence. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.